Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

WELCURE DRUGS & PHARMACEUTICAL

Healthcare › Pharmaceuticals & Biotechnology
₹0.19
at close · 28 Oct 2026
▲ 0.00 (+0.00%)

Latest filings

  1. Board approves closure of Ahmedabad Corporate Office · Board & Shareholder Meetings
  2. Company Secretary Palak Jain resigns from Welcure Drugs · Management Changes
  3. Company Secretary Palak Jain resigns from Welcure Drugs · Board & Shareholder Meetings
All filings ↓
Ask Nexa about WELCURE DRUGS & PHARMACEUTICAL

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹366 Cr over the trailing twelve months.

Market Cap
₹23 Cr
P / E (TTM)
0.1×
EV / EBITDA
—
Div Yield
—
Growth
387.1%▲
Revenue 5y CAGR
PAT — · EBITDA —
Quality
1.2%·
ROCE (5y median)
ROE 2.1% (5y median) · margin -1.5%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.58 Cr
Revenue FY21→FY26
2742.2×▲
Margin −42.8 pts
₹0 Cr → ₹366 Cr
Moves on a normal day
3.39%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#1/158
P/B#2/163
ROCE#158/183
ROE#151/166
Debt / Equity#1/166
Revenue growth#157/161
Profit growth#158/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 387% a year over 5 years
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Concerns
Erratic profits — up in only 2 of the last 5 years
Returns on capital 1.2% (5-year median)
#158 of 183 in Pharmaceuticals on the latest reported figures · down from 79.4% in FY21
Heavy working capital — 356 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from WELCURE DRUGS & PHARMACEUTICAL's filed financials and exchange disclosures

What does WELCURE DRUGS & PHARMACEUTICAL do?

WELCURE DRUGS & PHARMACEUTICAL is a Pharmaceuticals & Biotechnology company listed on BSE.

Is WELCURE DRUGS & PHARMACEUTICAL profitable?

No. Over the trailing twelve months WELCURE DRUGS & PHARMACEUTICAL reported a net loss of ₹17 Cr on revenue of ₹366 Cr.

Does WELCURE DRUGS & PHARMACEUTICAL pay a dividend?

Not in the latest reported year — WELCURE DRUGS & PHARMACEUTICAL's dividend payout for FY26 was nil.

Is WELCURE DRUGS & PHARMACEUTICAL debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.58 Cr of cash.

Is WELCURE DRUGS & PHARMACEUTICAL expensive compared with its peers?

On trailing P/E, WELCURE DRUGS & PHARMACEUTICAL ranks 1 of 158 in Pharmaceuticals — cheaper than 100% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the WELCURE DRUGS & PHARMACEUTICAL share price move in a day?

On a typical session WELCURE DRUGS & PHARMACEUTICAL moves 3.39% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track WELCURE DRUGS & PHARMACEUTICAL's announcements?

Every NSE and BSE filing by WELCURE DRUGS & PHARMACEUTICAL appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.